SITC's Cancer Immunotherapy Guidelines program is a collection of Clinical Practice Guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.
The Breast Cancer Immunotherapy Guideline Expert Panel was formed to generate consensus recommendations pertaining to the treatment of patients with breast cancer. In March 2019, accelerated approval was granted by the U.S. FDA for the checkpoint inhibitor atezolizumab in combination with chemotherapy for the treatment of PD-L1+ advanced or metastatic triple-negative breast cancer (TNBC)—the first immuno-oncology agent approval for this disease setting. Trials are ongoing evaluating other immunotherapeutic agents as monotherapies and combination regimens for the treatment of TNBC and other breast cancer subtypes. Reflecting the evolving therapeutic landscape, SITC is currently developing a breast cancer CPG with topics including selection of appropriate immunotherapeutic regimens, companion diagnostics, recognition and management of adverse events, and patient quality of life considerations.
Published August 13, 2021 in the Journal for ImmunoTherapy of Cancer (JITC) as "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer"
SITC is pleased to offer companion education resources in support of the breast cancer CPG. These activities feature faculty comprised of the guideline Expert Panel and are designed to provide a deeper understanding of the recommendations in the SITC guidelines and how to apply them in various clinical scenarios. The education available features both webinars that take a deeper look at the guideline recommendations and mini-module videos on a specific topic within the guideline content. Below is a list of the available educational resources for this CPG, available free and on-demand.Webinars:
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com